Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors  by Tornatore, Laura et al.
Cancer Cell
ArticleCancer-Selective Targeting of the NF-kB
Survival Pathway with GADD45b/MKK7 Inhibitors
Laura Tornatore,1 Annamaria Sandomenico,2 Domenico Raimondo,3 Caroline Low,4 Alberto Rocci,5
Cathy Tralau-Stewart,4 Daria Capece,1 Daniel D’Andrea,3 Marco Bua,6 Eileen Boyle,7 Mark van Duin,8 Pietro Zoppoli,9
Albert Jaxa-Chamiec,4 Anil K. Thotakura,1 Julian Dyson,10 Brian A. Walker,7 Antonio Leonardi,11 Angela Chambery,12,13
Christoph Driessen,14 Pieter Sonneveld,8 Gareth Morgan,7 Antonio Palumbo,5 Anna Tramontano,3,15 Amin Rahemtulla,6
Menotti Ruvo,2,* and Guido Franzoso1,*
1Department of Medicine, Centre for Cell Signalling and Inflammation, Imperial College London, London W12 0NN, UK
2Institute of Biostructures and Bioimages, National Research Council and CIRPeB, 80134 Naples, Italy
3Department of Physics, ‘‘Sapienza’’ University, 00185 Rome, Italy
4Drug Discovery Centre, Imperial College London, London W6 8RP, UK
5Division of Hematology, University of Torino, AOU San Giovanni Battista, 10126 Turin, Italy
6Department of Medicine, Centre for Haematology, Imperial College London, London W12 0NN, UK
7Section of Haemato-Oncology, The Institute of Cancer Research, London SM2 5NG, UK
8Department of Hematology, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands
9Institute for Cancer Genetics, Columbia University Medical Center, New York, NY 10032, USA
10Department of Medicine, Section of Molecular Immunology, Imperial College London, London W12 0NN, UK
11Department of Molecular Medicine and Medical Biotechnologies, University of Naples ‘‘Federico II,’’ 80131 Naples, Italy
12Department of Environmental, Biological, and Pharmaceutical Sciences and Technologies, Second University of Naples, 81100 Caserta,
Italy
13IRCCS Multimedica, 20138 Milan, Italy
14Department of Oncology/Hematology, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland
15Istituto Pasteur Fondazione Cenci Bolognetti, ‘‘Sapienza’’ University, 00185 Rome, Italy
*Correspondence: menotti.ruvo@unina.it (M.R.), g.franzoso@imperial.ac.uk (G.F.)
http://dx.doi.org/10.1016/j.ccr.2014.07.027SUMMARYConstitutive NF-kB signaling promotes survival in multiple myeloma (MM) and other cancers; however,
current NF-kB-targeting strategies lack cancer cell specificity. Here, we identify the interaction between
the NF-kB-regulated antiapoptotic factor GADD45b and the JNK kinase MKK7 as a therapeutic target in
MM. Using a drug-discovery strategy, we developed DTP3, a D-tripeptide, which disrupts the GADD45b/
MKK7 complex, kills MM cells effectively, and, importantly, lacks toxicity to normal cells. DTP3 has similar
anticancer potency to the clinical standard, bortezomib, but more than 100-fold higher cancer cell specificity
in vitro. Notably, DTP3 ablates myeloma xenografts in mice with no apparent side effects at the effective
doses. Hence, cancer-selective targeting of the NF-kB pathway is possible and, at least for myeloma
patients, promises a profound benefit.INTRODUCTION
In addition to orchestrating immune and inflammatory re-
sponses, NF-kB transcription factors play a crucial role in onco-
genesis (Staudt, 2010). NF-kB is aberrantly activated in a wide
range of human cancers, in which it promotes survival and
malignancy by upregulating antiapoptotic genes (Staudt,Significance
NF-kB has been implicated in many inflammatory and maligna
pathway has proved an insurmountable challenge. The conun
in a disease-specific manner, given NF-kB’s pleiotropic and
the context of MM. Rather than targeting NF-kB, we targeted
genically critical and cancer-restricted axis of the NF-kB pa
both highly effective against MM and well tolerated in vivo, wit
itors. Plausibly, the same principle could be applied for targetin
C2010; DiDonato et al., 2012). The paradigm of these cancers
is multiple myeloma (MM), an incurable malignancy of plasma
cells (PCs), accounting for nearly 2% of all cancer deaths (Kuehl
and Bergsagel, 2002). The current treatment for MM includes
chemotherapy and steroids combined with newer agents,
such as proteasome inhibitors and immunomodulatory drugs
(IMiDs), whereas stem cell transplantation is an option for selectnt diseases, such as MM. Yet therapeutically targeting this
drum with current strategies has been how to block NF-kB
ubiquitous functions. Here, we have achieved this goal in
the downstream module, GADD45b/MKK7, within a patho-
thway. We demonstrate that agents targeting this axis are
h far greater cancer cell specificity than global NF-kB inhib-
g NF-kB disease selectively also in pathologies beyondMM.
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Cancer-Selective Targeting of the NF-kB Pathwaypatients. These treatments, however, generally achieve only
temporary remissions, and so most patients eventually relapse
and/or develop drug resistance (Rajkumar, 2011; Mahindra
et al., 2012). Thus, despite the introduction of new treatments,
the management of myeloma patients remains a major medical
problem. Consequently, there is a need for more effective ther-
apeutic approaches targeting defined oncogenetic events
in MM.
Compelling evidence has established the paramount impor-
tance of aberrant NF-kB signaling in MM pathogenesis (Staudt,
2010; DiDonato et al., 2012). The most conclusive affirmation
of this key role of NF-kB in MM has come from the discovery
of a diverse array of genetic alterations targeting components
of the NF-kB pathway, such as the upstream activator, NF-kB-
inducing kinase and the inhibitor tumor necrosis factor recep-
tor-associated factor 3, in about 20% of MM patients and
more than 40% of MM cell lines (Annunziata et al., 2007; Keats
et al., 2007; Demchenko et al., 2010; Chapman et al., 2011). Irre-
spective of their nature, these oncogenic lesions lead to consti-
tutive activation of both main pathways of NF-kB signaling,
namely, the classical and alternative pathways (Keats et al.,
2007; Annunziata et al., 2007; Staudt, 2010; DiDonato et al.,
2012). In fact, even in those patients with no recognizable NF-
kB-pathway mutations, MM cells constitutively engage these
pathways via stimuli emanating from the tumor microenviron-
ment (Hideshima et al., 2005; Staudt, 2010). Consequently,
more than 80% of all primary MM cells and the vast majority
of MM cell lines display nuclear accumulation of NF-kB and
high NF-kB target gene signature, leading to NF-kB-pathway
addiction and sensitivity to apoptosis upon IkBa kinase (IKK) b/
NF-kB inhibition (Staudt, 2010).
Collectively, these findings provide a strong rationale for ther-
apeutically targeting the NF-kB pathway in MM. However,
despite the pharmaceutical industry’s aggressive effort to
develop specific NF-kB or IKKb inhibitors for indication both
within and outside of oncology, no such inhibitor has been clin-
ically approved, because of the preclusive toxicities associated
with the global suppression of NF-kB (DiDonato et al., 2012).
Similarly, proteasome inhibitors with clinical indication in MM,
such as bortezomib, inhibit many essential cellular pathways
that rely on proteasome function, among which is the NF-kB
pathway, and, furthermore, target these pathways in normal
and cancer cells alike, thus resulting in a low therapeutic index
and dose-limiting toxicities (Richardson, 2010; Chen et al.,
2011). Indeed, it is unclear that the clinical activity of proteasome
inhibitors in MM, as well as that of IMiDs, which too have broad
molecular specificity and can affect NF-kB signaling, is due to
the inhibition of NF-kB (Staudt, 2010; Chen et al., 2011;McCurdy
and Lacy, 2013).
The conundrum with conventional NF-kB-targeting strategies
has been how to achieve cancer cell specificity, given the ubiq-
uitous nature and pleiotropic physiological functions of NF-kB
(DiDonato et al., 2012). Because a key pathogenetic activity of
NF-kB in MM is to block apoptosis through the induction of
target genes, an attractive alternative to globally targeting NF-
kB would be to block the nonredundant, cancer-specific down-
stream effectors of the NF-kB survival function; these effectors,
however, are not known. To develop a strategy for inhibiting the
NF-kB pathway in a cancer-selective manner and, thus, exploit-496 Cancer Cell 26, 495–508, October 13, 2014 ª2014 Elsevier Inc.ing its therapeutic potential, we therefore sought to delineate
the mechanism(s) underlying the pathological survival activity
of constitutive NF-kB signaling in MM. Further, we sought to
develop a pharmacological inhibitor of this mechanism(s) in or-
der to kill MM cells effectively and without toxicity to normal
cells.
RESULTS
GADD45B Expression Denotes More Aggressive
Disease in MM
Given their key role in oncogenesis, we sought to investigate
the downstream mechanisms mediating NF-kB survival sig-
naling in MM. Because this signaling involves the induction of
antiapoptotic NF-kB target genes, and we had previously identi-
fied the GADD45-family gene, GADD45B, as a transcriptional
target of NF-kB encoding a potent and selective inhibitor of the
JNK MAPK pathway and, therefore, of apoptosis (De Smaele
et al., 2001; Papa et al., 2004), we investigated the involvement
of this gene in MM. GADD45B was markedly upregulated in
monoclonal CD138+ PCs from MM patients compared with
monoclonal PCs from patients with monoclonal gammopathy
of undetermined significance (MGUS), a premalignant condition
(Kyle and Rajkumar, 2009), or healthy polyclonal PCs (Figure 1A),
thus establishing a correlation between GADD45B mRNA
expression and PC malignancy. Strikingly, when MM patients
were stratified at diagnosis on the basis of the GADD45B
mRNA expression in CD138+ cells, the cohort of patients ex-
pressing high levels of GADD45B exhibited dramatically shorter
progression-free survival and significantly shorter overall survival
(OS) than the cohort of patients expressing low levels of
GADD45B, despite both groups of patients having been treated
with the same velcade/melphalan/prednisone protocol (Pal-
umbo et al., 2010) (Figures 1B and 1C). A similar correlation of
GADD45B expression with poor clinical outcome was observed
using two independent gene expression data sets of newly diag-
nosed MM patients, thus providing external validation of our
findings (Broyl et al., 2010; Dickens et al., 2010) (Figures S1A
and S1B available online). Collectively, these results establish
a strong correlation between GADD45B expression and disease
progression in MM and identify GADD45b as a hallmark of more
aggressive disease.
Constitutive NF-kBActivity Promotes the Survival ofMM
Cells by Inhibiting JNK Signaling
GADD45b inhibits apoptosis by suppressing JNK signaling. It
mediates this function by binding to the JNK kinase MKK7 and
blocking its enzymatic activity by engaging the kinase catalytic
pocket (Papa et al., 2004, 2007). This activity of GADD45b on
the JNK pathway and the elevated GADD45B mRNA levels
observed in monoclonal PCs from MM patients (Figure 1A)
prompted us to investigate whether GADD45bmediated an anti-
apoptotic crosstalk between the NF-kB and JNK pathways in
MM cells. We reasoned that cell extrinsic stimulation, as well
as intrinsic oncogenic signals and NF-kB-pathway mutations,
could result in the activation of signaling pathways beyond the
IKK/NF-kBcascade, such as the JNKpathway (Davies and Tour-
nier, 2012), which we and others have previously shown can
trigger apoptosis in a manner that can be suppressed by
Figure 1. GADD45B Is Highly Expressed in
MM Cells and Associates with Aggressive
Disease
(A) qRT-PCR showing the GADD45BmRNA levels
in monoclonal CD138+ cells from MM or MGUS
patients and polyclonal CD138+ cells (normal).
***p = 0.00018.
(B and C) Progression-free survival (B) and OS (C),
as defined by the International Myeloma Working
Group Uniform Response Criteria (Kyle and Raj-
kumar, 2009), in MM patients with low or high
GADD45B levels, as assessed by qRT-PCR, in
CD138+ cells. Patients were from the velcade/
melphalan/prednisone arm of the trial and strati-
fied at diagnosis, using as a cutoff the median
GADD45B expression value.
See also Figure S1.
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2004). Indeed, at least in principle, this mechanism could provide
a basis for the addiction of MM cells to NF-kB for survival. In line
with this hypothesis, in each of five heterogeneous MM cell lines
and a B lymphoblastoid cell line, the silencing of the NF-kB sub-
unit RelA (DiDonato et al., 2012) triggered JNK activation and
apoptosis (Figures S2A–S2C), and blocking this activation with
the JNK inhibitor SP600125 effectively protected NF-kB/RelA-
silenced MM cells from cell death (Figures S2D and S2E). Simi-
larly, the small hairpin RNA (shRNA)-mediated silencing of
MKK7 rescued MM cells from the cytotoxic effects of each of
two pharmacological inhibitors of IKKb/NF-kB, and the protec-
tive effect of this silencing was virtually complete (Figure S2F).
Collectively, these data indicate that constitutive NF-kB activity
promotes the survival of MM cells by inhibiting MKK7/JNK
signaling.
GADD45b as a Pivotal Survival Factor Downstream of
NF-kB and a Potential Therapeutic Target in MM
To investigate the possible contribution of GADD45b to MM
pathogenesis, we examined whether GADD45b mediated the
NF-kB-dependent survival function and inhibition of JNK
signaling in MM cells. As with PCs from patients (Figure 1A),
GADD45B was expressed at high levels in MM cell lines
compared with most other cancer cell lines tested (Figure S2G,
discussed below). Importantly, this high GADD45B expression
in MM cells markedly diminished upon the silencing of RelA,
thus demonstrating its dependence on constitutive NF-kB ac-
tivity (Figure 2A; Figure S2C). Moreover, similar to the effects
of RelA-targeting hairpins (Figures S2A–S2C), the introduction
of GADD45b-specific shRNAs, but not of MKK7-specific or ofCancer Cell 26, 495–508,nonspecific shRNAs, induced potent
JNK activation and apoptosis in all but
two of the MM cell lines tested, namely,
the RPMI-8226 and KMM-1 cell lines,
which exhibited almost undetectable
levels of GADD45b and significantly
lower levels of MKK7 than those
GADD45b-dependent MM cell lines (Fig-
ures 2B and 2C; Figures S2G–S2K,
further discussed below). Similar resultswere observed using additional GADD45b-targeting hairpins,
thus confirming the gene-silencing efficiency and specificity of
the shRNAs used (Figures S2H, S2J, S2L, and S2M). Strikingly,
the extent of JNK activation induced by the silencing of
GADD45b in sensitive MM cell lines was similar to that
observed with 12-O-tetradecanoylphorbol-13-acetate (TPA)/
ionomycin stimulation, which potently induces JNK (Figure 2C;
Figures S2I and S2J). By contrast, GADD45b downregulation
had no effect on IKK/NF-kB, ERK, or p38 activity. As seen
with the inhibition of IKKb/NF-kB (Figures S2D and S2E), both
the silencing of JNK1 and the treatment with SP600125 ef-
fectively reversed apoptosis in GADD45b-silenced MM cells
(Figures 2D and 2E; Figures S2N–S2P). Hence, GADD45b pro-
motes the survival of MM cells by inhibiting JNK-mediated
apoptosis. Collectively, these findings identify GADD45b as
an essential NF-kB-regulated survival factor and selective
MKK7/JNK-axis inhibitor and, therefore, as a potential thera-
peutic target in MM.
Development of D-Tetrapeptide Inhibitors of the
GADD45b/MKK7 Complex
Given the essential antiapoptotic role of GADD45b in MM and
our previous results showing that GADD45b suppresses JNK
signaling and apoptosis by blocking MKK7 via direct physical
interaction (De Smaele et al., 2001; Papa et al., 2004, 2007),
we aimed to develop selective inhibitors of this protein-protein
interaction in order to induce cytotoxic JNK signaling in MM
cells. We screened a simplified combinatorial library of 20,736
L-tetrapeptides to select compounds capable of disrupting the
GADD45b/MKK7 complex (Figure S3A and Table S1). Iterative
deconvolution of this library in ELISA competition assays,October 13, 2014 ª2014 Elsevier Inc. 497
(legend on next page)
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sulting hits, yielded two acetylated L-tetrapeptides of similar
structure, namely, Ac-LTP1 and Ac-LTP2, which disrupted the
GADD45b/MKK7 complex, in vitro, with remarkable half-
maximal inhibitory concentration (IC50) values in the subnano-
molar range (Figure 3A; Figure S3B and Table S2), in line with
the top-end potencies of other hits isolated from similar peptide
library screens (Houghten et al., 1999).
Next, we examined whether these two L-tetrapeptides re-
tained in vitro potency upon synthesis in the D configuration, a
strategy used successfully in some cases to render small pep-
tides resistant to proteolysis (Zhou et al., 2002; Nickl et al.,
2010). Strikingly, as shown in Figures 3A and 3B, the D-enantio-
mers of Ac-LTP1 and Ac-LTP2 (termed Ac-DTP1 and Ac-DTP2,
respectively) displayed no loss of activity in vitro and, unlike their
L counterparts, were highly stable in human serum, even after
prolonged incubation. Coimmunoprecipitation assays con-
firmed the potent and specific inhibitory effect of Ac-DTP1 and
Ac-DTP2 on GADD45b/MKK7 complex stability in vitro (Fig-
ure 3C). By contrast, control D-tetrapeptides had no such effect
on stability, thus demonstrating the specificity of the inhibitory
activities of Ac-DTP1 and Ac-DTP2. Crucially, the disruption of
the complex by these two active D-peptides completely
reversed the GADD45b-mediated inhibition of MKK7, fully
restoring the kinase catalytic activity (Figure 3D, top). Impor-
tantly, none of Ac-DTP1, Ac-DTP2, or any of the control D-tetra-
peptides affected MKK7 activity in the absence of GADD45b
(Figure 3D, bottom). Collectively, these findings identify a down-
stream, drug-targetable module in the NF-kB pathway and
confirm the potential of our pharmacological approach for
inducing cytotoxic MKK7/JNK signaling in cells that rely on
GADD45b for restraining MKK7 activation.
To verify the therapeutic potential of GADD45b/MKK7 inhibi-
tors, we aimed to improve their cell penetration. We replaced
the N-terminal acetyl group of Ac-DTP1 and Ac-DTP2 with a
benzyloxycarbonyl [Z] group, thereby generating z-DTP1 and
z-DTP2, respectively (Table S3), which retained high activity
and stability in vitro (Figures S4A and S4B) and, importantly,
also exhibited potent cytotoxic activity across a panel of genet-
ically heterogeneous MM cell lines (Figures 4A and 4B; Figures
S4C–S4F and Table S3). Significantly, z-DTP1 and z-DTP2, but
not a control D-tetrapeptide, induced potent and dose-depen-
dent toxicity in all of the MM cell lines tested, except the two ex-
pressing nearly undetectable levels of GADD45B and low levels
of MKK7 (further discussed below), exhibiting IC50 values in the
sensitive MM cell lines in the low nanomolar to low micromolar
range (Figures 4A and 4B; Figures S2G, S4E, and S4F). Consis-
tent with the protective mechanism mediated by GADD45b (Fig-Figure 2. GADD45b Mediates the NF-kB Survival Activity in MM Cells b
(A) qRT-PCR showing the GADD45BmRNA levels in MM cell lines expressing no
Values denote mean ± SD (n = 3).
(B) Survival of MM cell lines expressing sh-ns, GADD45b-specific (sh-GADD45b)
eGFP+ cells relative to the number of live eGFP+ cells in the same culture on day
(C) Western blots showing total and phosphorylated (P) proteins in U266 MM ce
(D) Trypan blue exclusion showing the survival of representativeMMcell lines coex
on day 8 after lentivirus infection. Values denote mean ± SD (n = 3).
(E) PI staining showing apoptotic cells (i.e., cells with sub-G1 DNA content) in r
depicted.
See also Figure S2.
Cure S2G), the z-DTP1- and z-DTP2-afforded killing of sensitive
MM cells was due to the induction of apoptosis (Figure 4C; Fig-
ures S4G and S4H). Importantly, both active D-peptides re-
tained potent and cancer-selective activity in primary PCs
from MM patients (Figure 4D, left). Crucially, these D-peptides
also exhibited an apparently complete lack of toxicity to normal
cells, even when used at very high concentrations (i.e., 100 mM;
Figure 4D, right; Figure S4I). Hence, D-tetrapeptide antagonists
of the GADD45b/MKK7 complex show exceptionally high activ-
ity and cancer cell specificity in terms of apoptosis induction in
MM cells, without displaying any apparent toxicity to normal
cells.
The Development of DTP3: A GADD45b/MKK7 Inhibitor
with Improved Bioavailability
To improve the bioavailability of D-peptides in vivo, while retain-
ing high cellular activity and specificity toward the GADD45b/
MKK7 complex, we used a chemical optimization strategy
based on structure-activity relationship and pharmacophore an-
alyses (Figures S5A–S5C and Table S4). By combining these
methods, we developed DTP3, a D-tripeptide with a molecular
weight of 525 Da (Figure 5A), which retained all the main char-
acteristics of the parental D-tetrapeptides in terms of bioactivity
and specificity, including subnanomolar activity and high stabil-
ity in vitro and potent and selective capacity to kill MM cells via
apoptosis (Figures S5D–S5H), while exhibiting a superior phar-
macokinetic profile compared with the parent molecules (dis-
cussed below).
We further evaluated the modality and specificity of the bind-
ing of DTP3 to the GADD45b/MKK7 complex. Circular dichro-
ism (CD) studies demonstrated that DTP3, but not a control
scrambled (SCRB) D-tripeptide, can physically interact with
and cause a significant conformational change of the structure
of this complex, as well as of the isolated MKK7 protein, in a
dose-dependent manner (Figure S5I). By contrast, DTP3 had
no effect on the CD signal of GADD45b (Figure S5I). MALDI-
TOF mass spectrometry confirmed the ability of DTP3 to bind
to MKK7, but not to GADD45b (Figure S5J). Spectrofluorimetric
analyses yielded similar results and, furthermore, established
the 1:1 stoichiometry and low equilibrium dissociation constant
(KD) value of the DTP3 interaction with MKK7 (Figure 5B; Fig-
ure S5K), thus underscoring the strength and specificity of this
interaction. Conversely, the SCRB D-tripeptide had no impact
on the fluorescence emission spectrum of MKK7, thus reaffirm-
ing the specificity of the effects of DTP3. Computational ana-
lyses predicted the presence of a pocket of MKK7, also found
on the GADD45b/MKK7 complex, that can bind to DTP3 (Fig-
ures S5L–S5T). Collectively, these results demonstrate thaty Suppressing JNK Signaling
nspecific (sh-ns) or RelA-specific (sh-RelA) shRNAs. JNK1 is shown as control.
, or MKK7-specific (sh-MKK7) shRNAs. Values express the percentage of live
0. Values denote mean ± SD (n = 3).
lls from (B). T/I, TPA/ionomycin.
pressing sh-GADD45b or sh-ns and JNK1-specific (sh-JNK1) or sh-ns shRNAs
epresentative MM cell lines from (D). The percentages of apoptotic cells are
ancer Cell 26, 495–508, October 13, 2014 ª2014 Elsevier Inc. 499
Figure 3. The Potent Activity and Stability of D-Peptide Inhibitors of GADD45b/MKK7 In Vitro
(A and B) ELISA GADD45b/MKK7 competition assays showing the IC50 values of the active L-tetrapeptides (Ac-LTP1, Ac-LTP2) and D-tetrapeptides (Ac-DTP1,
Ac-DTP2), before (A) and after (B) a 48 hr preincubation with human serum. Values express the percentage of inhibition of GADD45b binding to MKK7 relative to
the binding in the absence of peptide and denotemeans ± SD (n = 3). Ac-LNC, acetylated (Ac) negative control L-tetrapeptide (LNC); Ac-DNC, Ac negative control
D-tetrapeptide (DNC).
(C) Coimmunoprecipitations (IP) performed with cell lysates prepared from human embryonic kidney 293T cells expressing ectopic HA-tagged GADD45b (HA-
hGADD45b) and FLAG-taggedMKK7 (FLAG-hMKK7) and incubated with anti-FLAG antibody in the presence or absence of bioactive (Ac-DTP1 and Ac-DTP2) or
inactive (Ac-DNC, Ac-DNC2, Ac-DNC3 and Ac-DNC4) D-tetrapeptides, as indicated. Western blots were developed using anti-HA or anti-MKK7 antibodies. -,
incubation without D-tetrapeptides.
(D) Kinase assays (K.A.) showing MKK7 activity before (-) and after incubation with Ac-DTP1, Ac-DTP2 or control D-tetrapeptides as in (C), in the presence (+) or
absence of recombinant human (h)GADD45b. T/I, TPA/ionomycin; UT, untreated.
See also Figure S3 and Tables S1 and S2.
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isolation and within the complex with GADD45b, and support
a model whereby, upon binding to MKK7, DTP3 dissociates500 Cancer Cell 26, 495–508, October 13, 2014 ª2014 Elsevier Inc.the GADD45b/MKK7 complex via an allosteric mechanism,
potentially involving a conformational rearrangement of the
kinase.
Figure 4. The Potent and Cancer-Selective Activity of D-Peptide Inhibitors of GADD45b/MKK7 in MM Cells
(A) IC50 values of z-DTP1 and z-DTP2 at 144 hr, as determined by [
3H]thymidine incorporation, in MM cell lines that depend or do not depend on GADD45b for
survival.
(B) [3H]Thymidine incorporation showing the survival of representative sensitive (U266) and resistant (RPMI-8226) MM cell lines from (A) after a 6-day treatment
with the indicated concentrations of z-DTP1, z-DTP2, or Z-protected (z)-DNC.
(C) PI staining showing apoptotic cells in representative MM cell lines from (B), after treatment with 10 mM of z-DTP1, z-DTP2 or z-DNC for 6 days. The per-
centages of apoptotic cells are indicated.
(D) Trypan blue exclusion showing the survival of CD138+ cells fromMM patients (n = 8) and healthy human PBMCs after treatment with z-DTP1 or z-DTP2 for 48
and 144 hr, respectively.
(B and D) Values express the percentage of live cells present in the treated cultures relative to the live cells present in the respective untreated cultures, rep-
resented as 100%, and denote means ± SD (B), or SEM (D) [PBMCs] (n = 3), (D) [MM] (n = 8).
See also Figure S4 and Table S3.
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Figure 5. The High Target Specificity of
DTP3 in Cells
(A) The structure of DTP3.
(B) Tryptophan fluorescence quenching analysis
showing the dose-response curve of the -Dfluor-
escence values of GST-hMKK7 at 333 nm plotted
against the concentration values of DTP3. The
stoichiometry and KD value of the DTP3/MKK7
interaction on the basis of these data were 1:1 and
64.81 ± 6.22 nM, respectively. Values denote
means ± SD (n = 3).
(C) Correlation plot of the relative GADD45B
mRNA levels (qRT-PCR) and the DTP3 IC50 at
144 hr ([3H]thymidine incorporation) in cancer cell
lines of different tissues of origin. Values on the x
axis express the logarithm to base 10 (log10) of the
IC50. rS, Spearman correlation coefficient.
(D) K.A. showing JNK activity in representative
sensitive (KMS-12, U266) and resistant (RPMI-
8226) MM cell lines after treatment with DTP3
(10 mM). TNFa is shown as a positive control.
(E) Peptide pull-down showing the physical asso-
ciation of DTP3 with endogenous MKK7 in U266
andKMS-12MMcells. SCRBD-peptide is used as
a negative control. -, pull-down without D-tripep-
tide.
(F) [3H]Thymidine incorporation showing the sur-
vival of U266 and KMS-12 MM cells expressing
sh-ns or sh-MKK7 shRNAs after a 6-day treatment
with the indicated concentrations of DTP3. The
IC50 values of DTP3 are depicted. Values express
the percentage of the counts per minute (cpm)
measured with the treated cultures relative to the
cpm measured with the respective untreated cul-
tures and denote mean ± SD (n = 3).
See also Figure S5 and Tables S4 and S5.
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GADD45b/MKK7 Complex
In a panel of tumor cell lines of different tissues of origin, the
sensitivity to DTP3-induced killing correlated with a very high de-
gree of significance with the mRNA levels of GADD45B (Fig-
ure 5C; Figures S2G and S5U), which our data have shown is a
pivotal NF-kB-regulated inhibitor of MKK7/JNK signaling and
apoptosis in MM cells (Figures 2B–2E; Figures S2H–S2J and
S2N–S2P). Significantly, DTP3 displayed potent and selective
activity in both MM and non-MM cell lines exhibiting high levels
of GADD45B expression, whereas it was completely inactive,
even at high micromolar concentrations, in tumor cell lines
featuring low GADD45B expression (Figures S2G and S5F–
S5H). In the context of MM, the RPMI-8226 and KMM-1 cell
lines, which express very low levels of GADD45b and low levels502 Cancer Cell 26, 495–508, October 13, 2014 ª2014 Elsevier Inc.of MKK7 and are consequently unaf-
fected by GADD45b-targeting hairpins,
were completely refractory to DTP3-
induced killing (Figure 2B; Figures S2G–
S2I, S2K, and S5F–S5H).
As seen with GADD45b-silencing
shRNAs (Figure 2C; Figures S2H and
S2I), treatment with DTP3 effectively
activated JNK but not p38, ERK, or IKK/
NF-kB signaling in sensitive, GADD45b-dependent MM cell lines, whereas it did not affect any of these
pathways in DTP3-resistant, GADD45b-independent MM cell
lines, such as RPMI-8226 (Figure 5D; Figure S5V; see also Fig-
ure S4H, z-DTP2). Strikingly, the magnitude of the effects of
DTP3 on the JNK pathway was similar to that observed with tu-
mor necrosis factor a (TNFa), a potent inducer of JNK (Figure 5D;
Figures S4H and S5V, TPA/ionomycin). By contrast, a negative
control D-peptide had no effect on JNK signaling (Figure S5V).
As expected from the in vitro data (Figure 5B; Figure S5I, middle,
bottom; Figure S5J, left), these activating effects of DTP3 on the
JNK pathway hinged upon the ability of this D-tripeptide to bind
to MKK7 in cells, as shown by DTP3 pull-down assays (Fig-
ure 5E). These effects were not observed with the SCRB control
peptide, nor were they observed with a pull-down control in the
absence of peptide, thus demonstrating the specificity of the
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Cancer-Selective Targeting of the NF-kB Pathwaybinding of DTP3 to endogenous MKK7. Importantly, knocking
down the GADD45b target kinase, MKK7, or its downstream
effector, JNK1, completely abolished the cytotoxic activity of
DTP3 in sensitive MM cell lines (Figure 5F; Figures S5W and
S5X), thus excluding any off-target toxicity of DTP3 in cells.
DTP3 also lacked any off-target effect when profiled in kinase as-
says against a panel of 142 human kinases (Table S5). Hence,
bioactive D-peptides selectively induce apoptosis in MM cells
with functional MKK7 and elevated GADD45b expression by
activating JNK signaling via MKK7. These findings also correlate
the pharmacological activity of DTP3 with a tumor cell depen-
dence on GADD45b for survival and establish the exceptionally
high target specificity of this D-tripeptide for the GADD45b/
MKK7 complex in cells.
The Potent and Cancer-Selective Activity of DTP3 inMM
Cells from Patients
To verify the suitability of DTP3 for the treatment of human dis-
eases, we tested its activity and selectivity in MM PCs from pa-
tients. As seen with the active D-tetrapeptides (Figure 4D, left),
DTP3 effectively killed primary MM PCs at low nanomolar con-
centrations (Figures 6A and 6B). Importantly, it retained potent
and selective cytotoxic activity in these cells upon stimulation
with interleukin-6 or insulin growth factor 1 or coculture with
bone marrow stromal cells (BMSCs) (Figure 6C; Figures S6A
and S6B), which promote the survival of MM cells (Hideshima
et al., 2005). In order to compare the efficacy and cancer cell
specificity of DTP3 with the corresponding parameters of borte-
zomib, the current gold-standard treatment for MM (Chen et al.,
2011), we defined an ‘‘in vitro therapeutic index’’ (Figure 6A, bot-
tom). As shown in Figure 6A (top), DTP3 had a similar IC50 value to
bortezomib in primary MM PCs but, importantly, unlike bortezo-
mib, which barely discriminated between malignant and normal
cells, had no toxicity to normal cells. Strikingly, because of this
cancer cell selective target specificity, DTP3 had an in vitro ther-
apeutic index that was greater, by more than two orders of
magnitude, than that of bortezomib (Figure 6A, bottom). DTP3,
in fact, could also distinguish between PCs from MM and Wal-
denstro¨m’s macroglobulinemia (WM) patients (Kyle and Rajku-
mar, 2009), in line with the GADD45B expression levels in these
cells, whereas bortezomib could not (Figures 6A and 6B; Fig-
ure S6C). Similarly, DTP3 displayed farmore potent activity in pri-
mary MM PCs and far less toxicity to normal cells than the IKKb
inhibitor, PS-1145 (Figures 6C and 6D; Figures S6A and S6B;
note the different concentrations of DTP3 and PS-1145 used).
Because the standard MM treatment consists of combination
therapy, and nearly all patients will relapse and/or develop drug
resistance at some point, we evaluated the potential of DTP3 to
operate in these settings. As shown in Figures S6D and S6E,
DTP3 displayed synergistic activity with bortezomib in two
different MM cell lines, exhibiting a combination index of 0.21 in
U266 cells and of 0.56 in KMS-12 cells, suggesting that it could
find indication in the clinic in combination with bortezomib
(Chou, 2006). Importantly, DTP3 also retained full therapeutic ef-
ficacy in MM cell lines that were resistant to conventional MM
treatments, such as dexamethasone, bortezomib, and lenalido-
mide (Bjorklund et al., 2011, 2014, Ru¨ckrich et al., 2009) (Figures
S6F and S6G). Together, these results provide compelling evi-
dence of the high therapeutic potential of DTP3 in MM patients.CThe Potent Therapeutic Efficacy and Excellent
Tolerability of DTP3 against MM In Vivo
DTP3 showed high aqueous solubility and very high stability in
human serum, owing to its resistance to proteolysis, with a
good pharmacokinetic profile and excellent in vivo tolerability,
suitable for a therapeutic purpose (Figure 7A; Figure S5D and Ta-
ble S6).
Remarkably, in a plasmacytoma model, treatment with DTP3
at the dose of 14.5 mg/kg/day virtually eradicated established
subcutaneous myeloma xenografts in mice, in the absence of
any apparent side effects (Figures 7B and 7C; Figure S7A and
Table S6). Similar results were obtained in a second plasmacy-
toma model, generated using a different MM cell line (Figures
S7C and S7D). At the experimental end point, on day 28, all
the control mice had developed large local tumors, whereas all
the mice in the DTP3-treated cohort had shown a dramatic
shrinkage of the tumors (Figures 7B and 7C; Figures S7C and
S7D). This therapeutic effect of DTP3 was due to the potent
and tumor-selective induction of JNK activation and apoptosis
(Figures 7D and 7E; Figure S7B), as shown by the appearance
of phosphorylated JNK, as early as 24 hr of the onset of treat-
ment with DTP3, but not with PBS, followed by the appearance,
starting on day 3, of caspase-3 and PARP-1 proteolysis prod-
ucts. Coincident with these events, apoptotic cells became
evident in the tumor tissue at day 3 (Figure 7D; Figure S7B).
As well as the tumor-ablative effects of DTP3 (Figure 7B;
Figure S7A), the extent of this JNK-associated, tumor cell
apoptosismarkedly increased inmagnitude over time (Figure 7D;
Figure S7B).
Importantly, DTP3 retained potent anticancer activity in an
orthotopic xenograft model of MM, which more faithfully re-
capitulates the human disease. All the control mice developed
severe limb paralysis and died within 32 days of treatment
start, resulting in a median OS of 26 days (Figure 7F). Strikingly,
DTP3 administration over a period of 8 weeks, at a dose of
29 mg/kg/day, extended the median OS of the mice past the
experimental end point on day 161, without producing any
apparent side effect, thus demonstrating the potent therapeutic
efficacy of DTP3 against MM, in vivo, and the excellent tolera-
bility of this agent at doses that achieve full therapeutic efficacy.
Collectively, together with the data in primary MM cells (Figures
6A–6D; Figures S6A and S6B), these results underscore the po-
tency, safety, and cancer cell specificity of the pharmacological
approach targeting the GADD45b/MKK7 complex in MM and
identify DTP3 as a therapeutic selectively inhibiting the NF-kB
survival pathway in cancer (Figure 8).
DISCUSSION
We identified the GADD45b/MKK7 complex as a functionally
critical survival module downstream of NF-kB and a therapeutic
target in MM. Further, we developed a corresponding D-tripep-
tide inhibitor of this complex, DTP3, which effectively kills MM
cells by inducing MKK7/JNK-dependent apoptosis and, at the
same time, does not appear to be toxic to normal tissues.
Because of this cancer cell specificity, DTP3 displays an excep-
tionally high therapeutic index in vitro and potent and cancer-
selective activity against MM in vivo. Future studies will clarify
the precise mechanism by which DTP3 dissociates theancer Cell 26, 495–508, October 13, 2014 ª2014 Elsevier Inc. 503
Figure 6. The Potent Activity of DTP3 in Primary MMCells and Its Far Superior Cancer Cell Selectivity Compared with IKKb and Proteasome
Inhibitors
(A) IC50 values of DTP3 and bortezomib at 48 hr in CD138
+ cells fromMMpatients (n = 8), CD138+ cells fromWM patients (n = 2), human PBMCs, human BMSCs,
human mesenchymal stem cells (MSCs), and mouse splenocytes and lymph node (LN) cells (top), as determined by trypan blue exclusion. In vitro therapeutic
indices (IC50 in BMSCs/IC50 in MM PCs) are depicted (bottom). MM and WM PC values denote means ± SEM. Other values denote means (n = 3).
(B) Trypan blue exclusion showing the survival of CD138+ cells from representative patients from (A), after treatment with DTP3 or bortezomib for 48 hr.
(C) Trypan blue exclusion showing the survival of CD138+ cells from MM or WM patients after treatment with DTP3 (300 nM) or PS-1145 (20 mM) for 48 hr, in the
presence of BMSCs.
(D) Trypan blue exclusion showing the survival of primary human BMSCs, humanMSCs, andmouse LN cells and splenocytes after treatment with DTP3 (100 mM)
or PS-1145 (20 mM) for 144 hr.
(B–D) Values express the percentage of live cells present in the treated cultures relative to the live cells present in the respective untreated cultures and denote
means ± SD (B), (C) [WM], (D) (n = 3) or SEM (C) [MM] (n = 9).
See also Figure S6.
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Figure 7. DTP3 Exhibits Potent Therapeutic Activity against MM, In Vivo, in the Absence of Any Apparent Side Effects
(A) Pharmacokinetic (PK) values of DTP3 after single intravenous injection at the dose of 10 mg/kg. AUC, area under the plasma concentration versus time curve;
CL, plasma clearance; t1/2, terminal half-life; Vd, volume of distribution. Values denote means ± SD (n = 3).
(B) Volumes of subcutaneous U266myeloma xenografts in mice treated by continual infusion with DTP3 at a dose of 14.5 mg/kg/day or PBS for the times shown.
Values denote means ± SEM (n = 16). ***p < 0.001.
(C) Images of representative myeloma-bearing mice (top) and isolated tumors (bottom) from (B) at day 28.
(D) Images of TUNEL assays showing apoptotic cells in representative tumors from (B). Scale bars represent 10 mM. Green, TUNEL; blue, DAPI.
(E) Western blots showing total and phosphorylated (P) JNK, and the unprocessed (filled arrowheads) and cleaved (open arrowheads) forms of caspase-3 and its
proteolytic substrate, PARP-1, in representative tumors from (B).
(F) Percentage survival of mice bearing medullary KMS-12 MM xenografts and treated intermittently by infusion with DTP3 at a dose of 29.0 mg/kg/day or PBS
(left; n = 8, each group) for 8 weeks. Also shown is the median OS of each animal cohort (right). ***p < 0.0001.
See also Figure S7 and Table S6.
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Figure 8. Schematic Representation of the Therapeutic GADD45b/
MKK7-Targeting Strategy in Cancer
Depicted is the crosstalk between theNF-kBand JNK pathways promoting the
survival of cancer cells and cells exposed to inflammatory stimuli. Also illus-
trated is the NF-kB-dependent, Gadd45b/MKK7-mediated mechanism sup-
pressing apoptotic JNK signaling in MM cells. Our therapeutic strategy to
block the NF-kB survival function in a cancer-selective manner with DTP3
(green) is compared with conventional therapeutic approaches (e.g., IKKb and
proteasome inhibitors; red) also aimed at inhibiting the NF-kB pathway in
cancer. MAP3Ks, mitogen-activated protein kinase kinase kinases; ROS,
reactive oxygen species.
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Cancer-Selective Targeting of the NF-kB PathwayGADD45b/MKK7 complex. Notwithstanding, our findings un-
cover a mechanism for the pathogenetic survival activity of NF-
kB inMM. Crucially, they also demonstrate that cancer-selective
inhibition of theNF-kB survival pathway is possible and provide a
promising therapy with no preclusive toxicity that could be of
profound benefit for patients with this cancer and, potentially,
others for which NF-kB promotes survival via GADD45b (Lam
et al., 2005; Ngo et al., 2006; Tracey et al., 2005).
The therapeutic targeting of the NF-kB pathway has been
aggressively pursued for the treatment of a wide range of inflam-
matory and malignant pathologies, including MM (DiDonato
et al., 2012). However, it has proved so far an insurmountable
challenge. Current therapeutic approaches, such as IKKb inhib-
itors, target core components of this pathway, and so, although
they are potentially capable of abrogating the cancer-promoting
activities of NF-kB, they fail to preserve its pleiotropic physiolog-
ical functions, such as functions in immunity and inflammation
(Staudt, 2010; DiDonato et al., 2012). Because the best docu-
mented function of NF-kB in cancer is to induce genes that block
apoptosis and, despite its ubiquitous nature, NF-kB signaling
elicits highly tissue- and context-specific transcriptional pro-
grams (DiDonato et al., 2012), we sought to develop a thera-
peutic approach capable of inhibiting the NF-kB antiapoptotic
activity, in a cancer-selective manner. We reasoned that agents
targeting a nonredundant, downstream module within this crit-
ical survival axis of the NF-kB pathway and having functional re-
striction to the cancer cells (e.g., the GADD45b/MKK7 module in
the case of MM) would provide a more selective and, therefore,506 Cancer Cell 26, 495–508, October 13, 2014 ª2014 Elsevier Inc.more effective therapy, lacking the dose-limiting toxicities of
conventional drugs globally targeting NF-kB. It is noteworthy in
this regard that most normal cells do not express GADD45B
constitutively (Zhang et al., 2005). Furthermore, unlike mice lack-
ing RelA or any subunit of the IKK complex (DiDonato et al.,
2012), Gadd45b/ mice are viable, are fertile, and die of old
age (Papa et al., 2008; Lu et al., 2004), indicating that, in contrast
to global NF-kB blockade, complete GADD45b inactivation is
well tolerated in vivo.
Our approach also aims at exploiting the general good safety
of peptide therapeutics and the greater selectivity afforded by in-
hibiting a protein-protein interaction, rather than the entire func-
tion of a receptor or an enzyme, as is the case for most drugs.
Because of this property and their uniquemode of action, it is ex-
pected that the side effects of GADD45b/MKK7 inhibitors in pa-
tients will be milder than the phenotypes of Gadd45b/ mice
(Papa et al., 2008; Lu et al., 2004), both because of the transient
nature of chemotherapeutic treatments and because these
agents would enable GADD45b to retain its MKK7-independent
functions. The partially impaired TH1 T cell response reported in
Gadd45b/ mice (Lu et al., 2004), for example, was shown to
depend on the Gadd45b-afforded regulation of the MAP3K,
MEKK4 (Chi et al., 2004), but not of MKK7. Similarly, such agents
would enable MKK7 to retain its enzymatic function and
GADD45b-independent modalities of regulation. Nevertheless,
future studies will be required to address the potential side ef-
fects of DTP3 in patients.
Many cancers beyond MM rely on constitutive NF-kB
signaling for survival (Staudt, 2010; DiDonato et al., 2012).
Together, the high expression of GADD45B in a subset of these
cancers, including diffuse large B cell lymphoma (DLBCL) and
other types of lymphoma (Lam et al., 2005; Ngo et al., 2006;
Tracey et al., 2005), and the selective toxicity of DTP3 in DLBCL,
Burkitt’s lymphoma and promonocytic leukemia cell lines, imply
that GADD45b/MKK7 antagonists may have broader therapeutic
potential beyond MM, in other areas of unmet need within
oncology. By contrast, certain MM cell lines express low levels
of GADD45b, as well as of MKK7, and are refractory to DTP3-
induced killing. This suggests the existence of GADD45b-inde-
pendent mechanisms for NF-kB-dependent survival in certain
subtypes of MM and, most likely, in other types of malignancy.
For instance, BCL-2 family members are possible mediators of
such mechanisms, at least in the context of MM (Gomez-Bougie
and Amiot, 2013). Therefore, on the basis of the principle we
describe here of targeting an axis of the NF-kB pathway with
cancer-restricted function, rather than NF-kB globally, delin-
eating these mechanisms could provide new strategies for
targeting NF-kB in a disease-specific manner also in GADD45-
b-independent, NF-kB-addicted malignancies and, perhaps,
nonmalignant NF-kB-driven pathologies.
EXPERIMENTAL PROCEDURES
Cell Purification and Culture
Cells were cultured according to standard protocols (Mauro et al., 2011; Piva
et al., 2008). BMSCs and peripheral blood mononuclear cells (PBMCs) were
purified from MM patients or the blood of healthy volunteers, respectively,
as reported in Piva et al. (2008). CD138+ cells were purified from the bone
marrow aspirates of patients using CD138 MicroBeads (Miltenyi Biotech). Pa-
tients were recruited at the Hematology Division of ‘‘Ospedale San Giovanni
Cancer Cell
Cancer-Selective Targeting of the NF-kB PathwayBattista’’ (Turin, Italy) and the Haematology Clinic at Imperial College Health-
care NHS Trust, under the approval of the Ethics Committee of ‘‘Ospedale
San Giovanni Battista’’ (VMP-VMPT trial 163) and the London Harrow
Research Ethics Committee (11/LO/1628), respectively. Written consent was
documented for all subjects. Additional details are provided in Supplemental
Experimental Procedures.
Biochemical Assays
Quantitative RT-PCR (qRT-PCR) assays were carried out using the TaqMan
Gene Expression Assays kit (Applied Biosystems). The kinase profiling of
DTP3 across 142 human kinases was outsourced. Western blots, coimmuno-
precipitations, and kinase assays were performed as described previously
(Papa et al., 2004, 2008; Mauro et al., 2011). Additional details are provided
in Supplemental Experimental Procedures.
Cellular Assays
Lentiviral infections were performed using pLentiLox.3.7, as described by
Mauro et al. (2011). Enhanced GFP (eGFP)+ cells were purified, when neces-
sary, by fluorescence-activated cell sorting. [3H]Thymidine incorporation and
trypan blue exclusion assays were performed using standard methods (Mauro
et al., 2011). IC50 values were defined as themean concentration of compound
inducing 50% inhibition of cell viability relative to the viability in the untreated
cultures. Apoptosis analyses were performed using propidium iodide (PI)
staining, as described by Mauro et al. (2011). Additional details are provided
in Supplemental Experimental Procedures.
Peptide Synthesis and ELISA
Proteins were purified as described by Tornatore et al. (2008). The combinato-
rial L-tetrapeptide libraries and individual peptides were synthesized as re-
ported by Sandomenico et al. (2012). The methods used to assess peptide
identity and purity and deconvolute the tetrapeptide libraries and the ELISA
GADD45b/MKK7 competition assays were described previously (Sandome-
nico et al., 2012; Tornatore et al., 2008). IC50 values were defined as the
mean concentration of peptide inducing 50% inhibition of GADD45b binding
toMKK7 relative to the binding measured in the absence of peptide. Additional
details are provided in Supplemental Experimental Procedures.
DTP3 Binding Assays
The stoichiometry and KD value of the DTP3/MKK7 interaction were deter-
mined by tryptophan fluorescence quenching analysis, after fitting the fluores-
cence data with a nonlinear regression algorithm, as described by Williamson
(2013). Additional details are provided in Supplemental Experimental Proce-
dures, along with a description of the methods used for CD and MALDI-TOF
mass spectrometry analyses and the pull-down ofMKK7 from cells with DTP3.
Pharmacophore Analyses and Modeling
See Supplemental Experimental Procedures.
Pharmacokinetic Analyses
The pharmacokinetic analyses of DTP3 and z-DTP2 were outsourced. Addi-
tional details are provided in Supplemental Experimental Procedures.
Animal Studies
Mice were housed in the animal facilities at Hammersmith. All experiments
were conducted under Procedure Project License (PPL) 70/6874, after
approval by the Imperial College Ethical Review Process and the Home Office.
For the plasmacytoma model, nonobese diabetic/severe combined immuno-
deficiency mice (NOD.CB17-Prkdcscid/IcrCrl; Charles River) were injected
subcutaneously with 1.0 3 107 U266 or KMS-11 MM cells and then random-
ized into treatment groups and treated by infusion, as shown. Tumor volumes
were measured as described by Mauro et al. (2011). For the orthotopic MM
model, mice of the same strain were sublethally irradiated and then injected
intravenously with 1.0 3 107 KMS-12-BM MM cells, as described by Rabin
et al. (2007). Mice were then randomized into treatment groups and treated
by infusion for 8 weeks, as shown. Animals were monitored daily and eutha-
nized on day 161 of treatment start or when they reached any of the end points
in the PPL. Additional details are provided in Supplemental Experimental
Procedures.CStatistical Analyses
See Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and six tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.07.027.
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